Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Asker Healthcare Group AB ( (SE:ASKER) ) is now available.
Asker Healthcare Group reported a strong 2025, with net sales rising 12% to SEK 16.8bn and adjusted EBITA up 17%, lifting the margin to 9.5% for the year and 10% in the fourth quarter. Profit and earnings per share grew sharply, cash flow from operations improved, and return on net working capital stayed high, underscoring a stable core business and solid financial position.
Growth was driven by 14 acquisitions during the year, including four signed in the fourth quarter, alongside continuous operational improvements and economies of scale, particularly in the Central and West business areas. The group kept leverage below its 2.5x EBITDA target, proposed a dividend for shareholders and signalled an active M&A agenda for 2026 as it seeks to further consolidate the European medtech market and support efficiency and sustainability in healthcare.
The most recent analyst rating on (SE:ASKER) stock is a Hold with a SEK75.00 price target. To see the full list of analyst forecasts on Asker Healthcare Group AB stock, see the SE:ASKER Stock Forecast page.
More about Asker Healthcare Group AB
Asker Healthcare Group AB is a European medical technology and healthcare supplies group focused on delivering high-quality products and services to the healthcare sector. The company operates across several business areas, leveraging its scale, purchasing power and logistical expertise to support hospitals and care providers, while pursuing an active acquisition strategy to consolidate the European medtech market.
Average Trading Volume: 534,215
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK29.6B
Learn more about ASKER stock on TipRanks’ Stock Analysis page.